Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 5086 AL 5100

Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines

Davtyan H, Bacon A, Petrushina I, Zagorski K, Cribbs DH, Ghochikyan A, Agadjanyan MG.

Hum Vaccin Immunother. 2014;10(5):1248-55. doi: 10.4161/hv.27882. Epub 2014 Feb 13.

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease

Talbot K, Wang HY.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S12-25. doi: 10.1016/j.jalz.2013.12.007.

Vaccination against Alzheimer disease: an update on future strategies

Fettelschoss A, Zabel F, Bachmann MF.

Hum Vaccin Immunother. 2014;10(4):847-51. doi: 10.4161/hv.28183. Epub 2014 Feb 17.

Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study

Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group.

Phytomedicine. 2014 May 15;21(6):888-92. doi: 10.1016/j.phymed.2014.01.003. Epub 2014 Feb 16.

D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease

Kumar J, Sim V.

Prion. 2014 Jan-Feb;8(1):119-24. doi: 10.4161/pri.28220.

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan R, Vassar R.

Lancet Neurol. 2014 Mar;13(3):319-29. doi: 10.1016/S1474-4422(13)70276-X. Epub 2014 Feb 17.

The role of inflammasome in Alzheimer's disease

Liu L, Chan C.

Ageing Res Rev. 2014 May;15:6-15. doi: 10.1016/j.arr.2013.12.007. Epub 2014 Feb 19.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;2014(2):CD005380. doi: 10.1002/14651858.CD005380.pub5.

Why calcium channel blockers could be an elite choice in the treatment of Alzheimer's disease: a comprehensive review of evidences

Saravanaraman P, Chinnadurai RK, Boopathy R.

Rev Neurosci. 2014;25(2):231-46. doi: 10.1515/revneuro-2013-0056.

Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease

Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P.

Curr Drug Targets. 2014 May;15(5):539-50. doi: 10.2174/1389450115666140226112321.

Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies

Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F, Politi P.

ScientificWorldJournal. 2014 Jan 22;2014:174282. doi: 10.1155/2014/174282. eCollection 2014.

Retinoids as potential targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Biochem Behav. 2014 May;120:117-23. doi: 10.1016/j.pbb.2014.02.016. Epub 2014 Feb 26.

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

Adler G, Mueller B, Articus K.

Int J Clin Pract. 2014 Apr;68(4):465-70. doi: 10.1111/ijcp.12374. Epub 2014 Mar 3.

Alzheimer's disease prevention & acetyl salicylic acid: a believable story

Pomponi M, Pomponi MF.

Indian J Med Res. 2014 Jan;139(1):1-3.

Amyloid-ß-directed immunotherapy for Alzheimer's disease

Lannfelt L, Relkin NR, Siemers ER.

J Intern Med. 2014 Mar;275(3):284-95. doi: 10.1111/joim.12168.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias